secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0000950170-23-003293
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement
--------------------------------------------------------------------------------

- Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.
- Consulting fee of $8,000 per month; initial term one year, renewable at Company's option.
- Stock options continue vesting through Aug 31, 2023 (Jan 4, 2023 option through Jan 4, 2024); RSU vesting ceased on Feb 17, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/0000950170-23-003293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/clsd-20230217.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer